Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2008-001592-30-GB
EUCTR2008-001592-30-GBActive, not recruitingNot Applicable

A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered with or without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules

ovartis Vaccines and Diagnostics S.r.l.0 sites1,800 target enrollmentStarted: May 2, 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
1,800
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Healthy 2-month old infants (55-89 days, inclusive), who were born after full term pregnancy with an estimated gestational age = 37 weeks and a birth weight = 2.5 kg.
  • •2. For whom a parent/legal guardian has given written informed consent after the nature of the study has been explained.
  • •3. Available for all the visits scheduled in the study.
  • •4. In good health as determined by medical history, physical examination and clinical judgment of the investigator.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) no
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •1. History of any meningococcal B or C vaccine administration.
  • •2. Prior vaccination with any Diphtheria, Tetanus, Pertussis (acellular or whole cell), Polio (either Inactivated or Oral), Haemophilus influenzae type b (Hib), and Pneumococcal antigens.
  • •3. Previous ascertained or suspected disease caused by N. meningitidis.
  • •4. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis.
  • •5. History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component.
  • •6. Significant acute or chronic infection within the previous 7 days or axillary temperature = 38°C within the previous day.
  • •7. Antibiotics within 6 days prior to enrollment.
  • •8. Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, insulin dependent diabetes mellitus Type I, cardiac disease, hepatic disease, progressive neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition).
  • •9. Known or suspected impairment/alteration of the immune system, immunosuppressive therapy, use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids since birth;
  • •10. Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation.
  • •11. Receipt of, or intent to immunize with any other vaccine(s) (with the exception of rotavirus), within 30 days prior and throughout the study period.
  • •12. Participation in another clinical trial since birth or planned for during study.
  • •13. Family members and household members of research staff.
  • •14. Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.

Investigators

Sponsor
ovartis Vaccines and Diagnostics S.r.l.

Similar Trials

Active, not recruiting
Not Applicable
A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered with or without Routine Infant Vaccinations to Healthy Infants According to Different Immunization SchedulesThe Novartis Meningococcal B Recombinant + OMV NZ Vaccine is intended for prevention of meningitidis and/or septicemia caused by N.meningitidis serogroup B. The objective of the Novartis Meningococcal B Recombinant + OMV vaccine is to identify a vaccine candidate that is safe and provide functional immune responses against heterologous meningococcal B strains.MedDRA version: 9.1Level: LLTClassification code 10027276Term: Meningococcal meningitis
EUCTR2008-001592-30-BEovartis Vaccines and Diagnostics S.r.l.1,800
Active, not recruiting
Not Applicable
A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered with or without Routine Infant Vaccinations to Healthy Infants According to Different Immunization SchedulesThe Novartis Meningococcal B Recombinant + OMV NZ Vaccine is intended for prevention of meningitidis and/or septicemia caused by N.meningitidis serogroup B. The objective of the Novartis Meningococcal B Recombinant + OMV vaccine is to identify a vaccine candidate that is safe and provide functional immune responses against heterologous meningococcal B strains.MedDRA version: 9.1Level: LLTClassification code 10027276Term: Meningococcal meningitis
EUCTR2008-001592-30-CZovartis Vaccines and Diagnostics S.r.l.1,800
Active, not recruiting
Not Applicable
A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered with or without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules
EUCTR2008-001592-30-DEovartis Vaccines and Diagnostics S.r.l.1,800
Active, not recruiting
Not Applicable
A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered with or without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules - ND
EUCTR2008-001592-30-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.1,800
Active, not recruiting
Phase 1
A Clinical Study to Assess Immunologic and Virologic Changes in the Liver in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection.
EUCTR2019-004475-39-ITJanssen Sciences Ireland Unlimited Company24
A Phase 2b, Open Label, Randomized,... | Clinical Trial